Skip to main content

PHVS · Pharvaris N.V. · Metrics

Track PHVS — free
$31.60 -0.06 (-0.19%)
Market Cap
$2.24B
Shares
70.79M
Volume · Nov 20 218.81K Avg daily vol (3M) 755.25K

PHVS metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$31.66
Market cap
$2.24B

Price action

23 metrics
Price change (1W)
-6.4%
Price change (30D)
+3.3%
Price change (3M)
-13.0%
Price change (6M)
+3.7%
Price change (YTD)
+14.1%
Price change (1Y)
+29.0%
Trailing year
Price change (5Y)
+103.3%
52-week high
$38.86
52-week low
$23.68
Change from 52-week high
-18.5%
Change from 52-week low
+33.7%
Annualized volatility
52.5%
Annualized volatility (3M)
41.2%
Implied volatility (30D)
74.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.8
RSI (14D)
42.8
Price vs SMA 50
-3.6%
Price vs SMA 200
+0.7%
Avg volume (3M)
755,253
Relative volume
0.4
Average dollar volume
$26.02M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
70.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.5
reciprocal yield 15.3%
FCF yield
-8.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$168.56M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.16

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
−$181.14M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$363.38M
Total assets
$375.24M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$181.03M
Capital expenditures (TTM)
$115,781
R&D (TTM)
$150.61M
SG&A (TTM)
—
Stock compensation (TTM)
$24.44M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
135
13F filer change QoQ
+10
Institutional ownership
94.9%
Conviction holders (share of 13F filers)
11.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.4%
Holder tenure
12.6
Price vs estimated holder cost
+19.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
3.6%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$20.34M
Insider-sentiment score
3 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1830487 CUSIP N69605108 13F (30d) 150 filings 134 filers Visit website Investor relations